Trial Profile

Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2024 Results(n=91) discussing Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
02 Jun 2024 According to a Puma Biotechnology media release, data from this study were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting currently being held in Chicago.
02 Jun 2024 Results presented in a Puma Biotechnology Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com